FDA Sends Pathway Genomics Untitled Letter Over Liquid Biopsy Test | GenomeWeb

NEW YORK (GenomeWeb) – Pathway Genomics has received a letter (see PDF below) from the US Food and Drug Administration saying that it has concerns about a new liquid biopsy test for cancer offered by the company, as well as the way Pathway is marketing the test. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.